Corrigendum to 'Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.' Kidney Int. 2020;97:1287–1296
- Resource Type
- Source
- Kidney International. 99:1244
- Subject
Kidney medicine.medical_specialty Adult patients business.industry INT medicine.disease Gastroenterology Complement inhibitor medicine.anatomical_structure Long acting Nephrology Internal medicine Atypical hemolytic uremic syndrome Medicine Ravulizumab, Thrombotic microangiopathy, Pregnancy microangiopathies, Atypical hemolytic uremic syndrome business - Language
- ISSN
- 0085-2538